SGLT2 inhibitors: the latest "new kids on the block"!
作者信息
Cefalu William T, Riddle Matthew C
机构信息
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA
Oregon Health & Science University, Portland, OR.
出版信息
Diabetes Care. 2015 Mar;38(3):352-4. doi: 10.2337/dc14-3048.
Abstract
摘要
相似文献
1
SGLT2 inhibitors: the latest "new kids on the block"!钠-葡萄糖协同转运蛋白2抑制剂：最新的“新成员”！
Diabetes Care. 2015 Mar;38(3):352-4. doi: 10.2337/dc14-3048.
2
SGLT2 inhibitors in the treatment of type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病治疗中的应用
Diabetes Res Clin Pract. 2014 Jun;104(3):297-322. doi: 10.1016/j.diabres.2014.02.014. Epub 2014 Mar 11.
3
Benefits, risks of SGLT2 inhibitors explored at session.会议探讨了SGLT2抑制剂的益处和风险。
Am J Manag Care. 2014 Jul;20(10 Spec No):E11.
4
SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?钠-葡萄糖协同转运蛋白2抑制剂：为2型糖尿病提供心血管保护？
Lancet Diabetes Endocrinol. 2016 May;4(5):379-81. doi: 10.1016/S2213-8587(16)00084-X. Epub 2016 Mar 18.
5
[Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].[2型钠-葡萄糖协同转运蛋白（SGLT2）抑制剂在慢性肾脏病中的应用]
G Ital Nefrol. 2015 Jul-Aug;32(4).
6
Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病中的应用：游走于斯库拉和卡律布狄斯之间。
Expert Opin Emerg Drugs. 2014 Mar;19(1):5-9. doi: 10.1517/14728214.2014.875530. Epub 2014 Jan 8.
7
Comparison chart of SGLT2 inhibitors.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂比较表。
Med Lett Drugs Ther. 2017 Jan 30;59(1513):e26.
8
Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes.昼夜血压节律作为用于治疗2型糖尿病的钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的一个可能关键靶点。
Hypertens Res. 2016 Jun;39(6):396-8. doi: 10.1038/hr.2016.1. Epub 2016 Jan 28.
9
[SGLT2 inhibitors: a new therapeutic class for the treatment of type 2 diabetes mellitus].[钠-葡萄糖协同转运蛋白2抑制剂：治疗2型糖尿病的新型治疗类别]
Harefuah. 2015 Mar;154(3):200-3, 210.
10
The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病早期治疗中的潜在作用。
Int J Clin Pract. 2015 Oct;69(10):1071-87. doi: 10.1111/ijcp.12675. Epub 2015 Jul 5.
引用本文的文献
1
SGLT-2 Inhibitors and the Inflammasome: What's Next in the 21st Century?SGLT-2 抑制剂与炎症小体：21 世纪的下一个前沿？
Nutrients. 2023 May 13;15(10):2294. doi: 10.3390/nu15102294.
2
The Anti-Inflammatory Effect of Novel Antidiabetic Agents.新型抗糖尿病药物的抗炎作用
Life (Basel). 2022 Nov 9;12(11):1829. doi: 10.3390/life12111829.
3
Fournier Gangrene in a Patient With Type 2 Diabetes Mellitus Treated With Dapagliflozin: A Case Report.达格列净治疗2型糖尿病患者并发福尼尔坏疽：一例报告
Ann Coloproctol. 2021 Jul;37(Suppl 1):S48-S50. doi: 10.3393/ac.2020.06.22. Epub 2021 May 28.
4
Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease.钠-葡萄糖协同转运蛋白 2 抑制剂对缺血性心脏病的疗效。
Diabetes Obes Metab. 2020 Jul;22(7):1197-1206. doi: 10.1111/dom.14025. Epub 2020 Mar 31.
5
A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus.一名服用卡格列净治疗2型糖尿病的患者发生福尼尔坏疽的病例。
Am J Case Rep. 2020 Feb 24;21:e920115. doi: 10.12659/AJCR.920115.
6
Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis.达格列净诱发的迟发性正常血糖性糖尿病酮症酸中毒。
Cureus. 2019 Nov 7;11(11):e6089. doi: 10.7759/cureus.6089.
7
Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients.新型降糖药物在高危患者中的心血管和肾脏结局。
Curr Cardiol Rep. 2018 Jun 21;20(8):65. doi: 10.1007/s11886-018-1005-8.
8
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.SGLT2 抑制剂的直接心血管影响：机制和效应。
Heart Fail Rev. 2018 May;23(3):419-437. doi: 10.1007/s10741-017-9665-9.
9
Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.钠-葡萄糖协同转运蛋白2抑制剂长期治疗的有效性：来自一家专业糖尿病中心的真实世界证据。
Diabetol Metab Syndr. 2017 Dec 1;9:96. doi: 10.1186/s13098-017-0297-y. eCollection 2017.
10
Canagliflozin: A Review in Type 2 Diabetes.卡格列净：用于 2 型糖尿病的药物评价。
Drugs. 2017 Sep;77(14):1577-1592. doi: 10.1007/s40265-017-0801-6.
本文引用的文献
1
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.血压降低：2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂的额外益处。
Diabetes Care. 2015 Mar;38(3):429-30. doi: 10.2337/dc14-1596.
2
Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂联合二肽基肽酶-4（DPP-4）抑制剂的联合疗法在2型糖尿病管理中处于什么地位？
Diabetes Care. 2015 Mar;38(3):373-5. doi: 10.2337/dc14-2517.
3
Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.恩格列净和利拉利汀联合治疗 2 型糖尿病患者。
Diabetes Care. 2015 Mar;38(3):394-402. doi: 10.2337/dc14-2365. Epub 2015 Jan 29.
4
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.达格列净改善了二甲双胍联合磺酰脲类药物治疗的血糖控制并减轻体重：一项 24 周随机、双盲临床试验。
Diabetes Care. 2015 Mar;38(3):365-72. doi: 10.2337/dc14-0666. Epub 2015 Jan 15.
5
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.恩格列净和利拉利汀联合治疗二甲双胍控制不佳的 2 型糖尿病患者。
Diabetes Care. 2015 Mar;38(3):384-93. doi: 10.2337/dc14-2364. Epub 2015 Jan 12.
6
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.2015年2型糖尿病高血糖管理：以患者为中心的方法：美国糖尿病协会和欧洲糖尿病研究协会立场声明更新版
Diabetes Care. 2015 Jan;38(1):140-9. doi: 10.2337/dc14-2441.
7
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.钠-葡萄糖共转运蛋白 2 抑制剂坎格列净联合胰岛素治疗 2 型糖尿病患者的疗效和安全性。
Diabetes Care. 2015 Mar;38(3):403-11. doi: 10.2337/dc14-1237. Epub 2014 Dec 2.
8
The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes.2012 年升高的血糖水平的经济负担：诊断和未诊断的糖尿病、妊娠糖尿病和糖尿病前期。
Diabetes Care. 2014 Dec;37(12):3172-9. doi: 10.2337/dc14-1036.
9
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.二甲双胍单药治疗血糖控制不佳的 2 型糖尿病的双联附加治疗：一项比较沙格列汀加达格列净双联附加治疗与沙格列汀或达格列净单药附加治疗加至二甲双胍的随机、双盲试验。
Diabetes Care. 2015 Mar;38(3):376-83. doi: 10.2337/dc14-1142. Epub 2014 Oct 28.
10
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.探索 SGLT2 抑制剂达格列净在 1 型糖尿病中的潜力：一项随机、双盲、安慰剂对照的初步研究。
Diabetes Care. 2015 Mar;38(3):412-9. doi: 10.2337/dc13-2955. Epub 2014 Sep 30.
Zotero 插件